Ayisha Sharma is a News Reporter at Endpoints. She focuses on the UK and Europe biopharma space, with a keen interest in psychiatric drug R&D, while also covering themes related to pharmaceuticals, healthcare systems, and mental health. Ayisha's work has been featured in Endpoints News, Citeline, The Guardian, and NewsBreak.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Ayisha Sharma's coverage is primarily focused on the healthcare and pharmaceutical industry, with a strong emphasis on corporate developments, clinical trials, and regulatory actions. Her articles largely feature press releases and cite data from private sector announcements. Therefore, she may be particularly interested in pitches that provide exclusive access to breaking news within the pharmaceutical or biotech industries.
Given her focus on specific companies' activities such as licensing deals, FDA warnings, bankruptcies, and legal disputes within the healthcare sector; experts who have insights into these areas would likely capture her attention.
Ayisha's reporting does not seem to have a geographic focus but rather covers global developments in the pharmaceutical and biotech sectors.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ayisha Sharma
Argenx's Vyvgart Hytrulo hits its Phase 3 primary endpoint in autoimmune myositis, though the DM subgroup missed statistical significance.
By: Ayisha Sharma
News Reporter Leo Pharma said it will pay Japan's Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a …
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
FDA grants Ultragenyx's Genglycos accelerated approval, its first gene therapy, for GSDIa in patients 8 and up; list price $2.7M.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
By: Ayisha Sharma
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
